Accumulating evidence has suggested that various anti-estrogens such as tamoxifen, raloxifen, and fulvestrant (ICI 182.780) function as GPR30 agonists, similar to E2, which in turn leads to cancer cell proliferation, migration, and invasion [37]. This evidence concerns the gene GPER1 and cancer.